1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst

It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.If you're looking for a stock that could make dramatic gains in the foreseeable future, consider this biopharmaceutical player that has been having a lousy year so far.Shares of Apellis Pharmaceuticals (APLS 2.47%) are down by about 62% from the peak they reached in January. However, investment bank analysts who follow the drugmaker think its best days are still ahead. Bank of America recently put a $61 per share pr ...